LONDON, April 26, 2012 /PRNewswire/ --
EvaluatePharma Ltd, a leading source for life science sector analysis and the first to supply reliable consensus forecasts of global drug sales, revealed today that Novartis is expected to take the top spot amongst the world's pharmaceuticals manufacturers, in terms of prescription (Rx) drug sales, starting in 2014 and remains at the top through 2018. Only one US-based drug maker, Pfizer, will rank among the top five, with Sanofi, GlaxoSmithKline and Roche also topping the table. Further down the league table sizeable shifts both up and down the rankings are forecast, as pipeline successes and failures drive the future fortunes of the world's biggest pharma companies (see table).
For more in-depth analysis and commentary on this news please visit EP Vantage: http://ow.ly/awKnz.
World's Top 15 Pharma Companies
Market Rank Rx Pharma Sales ($bn)
Annual
growth
2011 2014 2016 2018 2011 2014 2016 2018 2011-18
Novartis 2 1 1 1 46.7 47.6 49.0 50.8 1.2%
Sanofi 4 3 3 2 39.3 42.9 45.6 47.8 2.9%
Pfizer 1 2 2 3 53.5 46.9 46.5 47.1 -1.8%
GlaxoSmithKline 6 6 4 4 35.0 38.5 43.1 45.6 3.9%
Roche 5 5 5 5 37.0 40.7 42.7 45.0 2.8%
Merck & Co 3 4 6 6 41.9 40.9 42.6 41.0 -0.3%
Johnson &
Johnson 9 8 7 7 22.3 25.8 27.2 27.3 2.9%
Teva 11 10 10 8 17.1 22.1 22.8 23.3 4.5%
AstraZeneca 7 7 8 9 32.4 26.7 25.2 22.1 -5.3%
Abbott
Laboratories 8 9 9 10 22.4 23.7 23.9 22.1 -0.2%
Bristol-Myers
Squibb 12 15 11 11 16.9 14.9 18.9 21.4 3.4%
Novo Nordisk 17 14 13 12 12.4 15.6 18.0 19.9 7.0%
Takeda 14 12 12 13 15.2 16.8 18.7 19.5 3.6%
Bayer 16 16 16 14 13.6 14.6 15.7 16.5 2.7%
Gilead Sciences 21 20 17 15 8.1 10.8 15.0 15.7 9.9%
About EvaluatePharma Ltd.
The market intelligence and analysis company EvaluatePharma Ltd was the first to supply reliable consensus forecasts of global drug sales and has just updated the standardized worldwide financial and forecast models with consensus product sales forecasts to 2018. EvaluatePharma also provides data on R&D pipelines, clinical trials, licensing deals, patent risk, M&A activity, valuation through product Net Present Value analysis plus daily commentary and analysis from the EP Vantage® news service.
EvaluatePharma Ltd, headquartered in London, England and in North America is represented by EvaluatePharma USA, Inc.
Media Contacts:
Andrew Beaven
Marketing Director, EvaluatePharma Ltd
Tel: +44(0)20-7377-0800
Email: andrewb@evaluatepharma.com
EvaluatePharma Ltd
11-29 Fashion Street
London
E1 6PX
United Kingdom
Christine Lindgren
Tel: +1-617-573-9458
Email: christinel@evaluatepharma.com
EvaluatePharma USA
15 Broad St.
Boston, MA 02109
United States
SOURCE EvaluatePharma Ltd
